This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
When these two medicines are taken together, your body may not absorb your digitalis glycoside properly.
What might happen:
Your blood levels of digitalis glycoside may decrease. This may decrease the beneficial effects of your digitalis glycoside.
What you should do about this interaction:
If you experience shortness of breath or a fast heartbeat, contact your doctor. Your doctor may check your blood level of digitalis glycoside and adjust the dose of your medicine. It may be necessary to change the time you take each medicine.Your healthcare professionals (e.g. doctor or pharmacist) may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Bazzano G, Bazzano GS. Digitalis intoxication. Treatment with a new steroid-binding resin. JAMA 1972 May 8;220(6):828-30.
2.Brown DD, Juhl RP, Warner SL. Decreased bioavailability of digoxin produced by dietary fiber and cholestyramine. Am J Cardiol 1977 Feb; 39(2):297.
3.Klotz U, Antonin KH. Biliary excretion studies with digoxin in man. Int J Clin Pharmacol Biopharm 1977 Jul;15(7):332-4.
4.Brown DD, Juhl RP, Warner SL. Decreased bioavailability of digoxin due to hypocholesterolemic interventions. Circulation 1978 Jul;58(1):164-72.
5.Cady WJ, Rehder TL, Campbell J. Use of cholestyramine resin in the treatment of digitoxin toxicity. Am J Hosp Pharm 1979 Jan;36(1):92-4.
6.Carruthers SG, Dujovne CA. Cholestyramine and spironolactone and their combination in digitoxin elimination. Clin Pharmacol Ther 1980 Feb; 27(2):184-7.
7.Pieroni RE, Fisher JG. Use of cholestyramine resin in digitoxin toxicity. JAMA 1981 May 15;245(19):1939-40.
8.Payne VW, Secter RA, Noback RK. Use of colestipol in a patient with digoxin intoxication. Drug Intell Clin Pharm 1981 Nov;15(11):902-3.
9.Kilgore TL, Lehmann CR. Treatment of Digoxin intoxication with colestipol. South Med J 1982 Oct;75(10):1259-60.
10.Baciewicz AM, Isaacson ML, Lipscomb GL. Cholestyramine resin in the treatment of digitoxin toxicity. Drug Intell Clin Pharm 1983 Jan; 17(1):57-9.
11.Kuhlmann J. Use of cholestyramine in three patients with beta-acetyldigoxin, beta- methyldigoxin and digitoxin intoxication. Int J Clin Pharmacol Ther Toxicol 1984 Oct;22(10):543-8.
12.Brown DD, Schmid J, Long RA, Hull JH. A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. J Clin Pharmacol 1985 Jul-Aug;25(5):360-4.
13.Henderson RP, Solomon CP. Use of cholestyramine in the treatment of digoxin intoxication. Arch Intern Med 1988 Mar;148(3):745-6.
14.Neuvonen PJ, Kivisto K, Hirvisalo EL. Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide. Br J Clin Pharmacol 1988 Feb;25(2):229-33.
15.Lanoxin (digoxin) Tablets US prescribing information. GlaxoSmithKline August, 2012.